Handling an FDA Inspection: Practice Test

Answer: Yes, the facility must admit the investigator.

Explanation: Under Section 704(a) of the FD&C Act, FDA investigators are authorised to enter and inspect any factory, warehouse, or establishment in which drugs or medical devices are manufactured, processed, packed, or held. Admission cannot be conditioned on the availability of a particular employee. The facility must designate an appropriate representative to accompany the investigator. Refusing entry or delaying admission without legal justification is a refusal to permit inspection, which constitutes a prohibited act under Section 301(f) of the FD&C Act and can result in enforcement action.

Answer: Yes, for records required by GMP regulations.

Explanation: Under Section 704(a) of the FD&C Act, FDA investigators may inspect and copy records required under the Act. GMP regulations under 21 CFR Parts 211 and 820 require manufacturers to maintain training records demonstrating that employees are qualified for their assigned functions. These records are required by regulation and therefore subject to FDA inspection. However, FDA’s access to records is not unlimited. Internal audit records have historically been protected under a specific FDA policy, though this protection has been narrowed under the new QMSR inspection approach for medical devices.

Answer: Form 482 is the official notice of FDA inspection. The facility should acknowledge receipt, designate an inspection host and team, and begin the inspection process.

Explanation: FDA Form 482, Notice of Inspection, is the document investigators present at the start of an inspection. It identifies the investigator’s credentials, the regulatory authority for the inspection, and the scope of the inspection if specified. Upon receiving Form 482, the facility should acknowledge receipt in writing, assemble the inspection team (typically quality management, regulatory affairs, and operations), notify senior management, and begin accompanying the investigator. The facility should not attempt to delay the start of the inspection or restrict the investigator’s access to required areas and records.

Answer: A routine surveillance inspection is scheduled based on FDA’s inspection cycle. A for-cause inspection is triggered by a specific complaint, adverse event, recall, or other signal. Both require the same level of cooperation, though for-cause inspections typically focus on specific areas.

Explanation: Routine inspections occur as part of FDA’s regular facility monitoring programme. For-cause inspections are initiated in response to a specific trigger such as a complaint, an MDR or MedWatch report, a recall, or information suggesting a compliance problem. During a for-cause inspection, investigators typically focus their review on the area of concern that triggered the inspection. However, if they identify additional issues during the inspection, they may expand their review. The facility’s obligation to cooperate fully applies equally to both inspection types.

Answer: The operator should answer only what they know with certainty, say they do not know if they are uncertain, and offer to have a knowledgeable colleague provide the information.

Explanation: Employees interviewed during FDA inspections should answer questions honestly and directly. They should not guess, speculate, or provide information they are not certain about. If an employee does not know the answer to a question, the correct response is to say so and direct the investigator to the person with the relevant knowledge. Attempting to answer questions that the employee is not qualified to answer can produce inaccurate information that the investigator records and references in the inspection report. All employees who may interact with FDA investigators should be trained on this principle.

Answer: Photographs may generally be permitted at the facility’s discretion, but the facility is not required to allow photography. The quality manager should consult with management or legal counsel before allowing or refusing.

Explanation: FDA investigators do not have an automatic right to photograph facility interiors under the FD&C Act. The facility may permit photography as a courtesy or as a practical means of documenting observations. If the facility allows photography, it should document what was photographed. If the facility declines to allow photography, it should do so respectfully and offer to provide written descriptions or other documentation of what the investigator wishes to record. Refusing photography that would not reveal confidential commercial information may create an adversarial dynamic that is generally not in the facility’s interest.

Answer: Respectfully explain the correct interpretation with supporting documentation. Do not argue, and do not dismiss the concern.

Explanation: When investigators identify potential issues, the facility’s first response should be to listen, understand exactly what the investigator has identified, and then provide context and documentation if the concern is based on a misunderstanding. If the investigator’s concern is valid, acknowledging it promptly and offering to investigate demonstrates a positive quality culture. If the facility believes the investigator has reached an incorrect conclusion, the correct approach is to respectfully provide clarifying information with documentation, not to argue. Disputes about findings that cannot be resolved during the inspection can be raised through the FDA’s post-inspection dispute resolution process.

Answer: The facility has lost the opportunity to monitor and clarify what was communicated to FDA, and the employee’s statements about undocumented deviations may result in inspection findings that would not otherwise have been identified.

Explanation: Best practice during FDA inspections is to have a quality or regulatory affairs representative accompany the investigator throughout the inspection, including during employee interviews where possible. This allows the facility to understand what information was conveyed to the investigator, provide clarifying context where needed, and take notes for the inspection record. When employees are interviewed without a representative present, statements that are incomplete, inaccurate, or that reveal previously undisclosed compliance issues may significantly affect the inspection outcome. Training all employees on what to say and how to say it reduces this risk.

Answer: Submit a written response to FDA within 15 business days addressing all five observations, including a respectful explanation of the facility’s position on the two disputed observations with supporting documentation.

Explanation: A Form 483 is a list of inspectional observations, not a final regulatory determination. The facility has the opportunity to respond in writing, ideally within 15 business days. The response should address every observation with specific corrective actions, timelines, and responsible parties. For observations the facility disputes, the response should explain the facility’s position clearly and provide documentation supporting the alternative interpretation. FDA will review the response and determine whether the observations are adequately addressed. A well-documented response that provides substantive corrective actions and, where appropriate, well-reasoned challenges to specific observations, can prevent observations from escalating to Warning Letter citations.

Answer: Repeat violations significantly increase enforcement risk, including import alert, consent decree, product seizure, and criminal referral.

Explanation: When FDA cites the same or substantially similar violations in multiple consecutive inspections, it signals to the agency that the facility’s quality system is not self-correcting. Repeat violations are a significant escalation factor in FDA’s enforcement decision making. After a Warning Letter for repeat violations, FDA may place the facility on import alert (preventing distribution of its products into the United States), seek a consent decree of permanent injunction requiring court supervision of the facility’s operations, initiate product seizure, or refer the matter for criminal prosecution. Responding to a Warning Letter for repeat violations requires demonstrating not just that the specific violation was corrected, but that the quality system is fundamentally improved.

Answer: FDA typically expects a response within 15 working days of receipt. Failure to respond, or an inadequate response, increases the likelihood of escalated enforcement action.

Explanation: FDA Warning Letters request a written response within 15 working days, though this timeline may vary. The response must address every violation cited in the Warning Letter with specific corrective actions and timelines. An inadequate response, one that is vague, promises future action without specifics, or does not address all cited violations, carries similar risk to no response. FDA publishes Warning Letters publicly, and an unresolved Warning Letter affects the facility’s ability to pursue regulatory submissions, obtain new product approvals, and maintain customer and investor confidence. Engaging experienced regulatory counsel to assist with Warning Letter responses is common practice for complex enforcement situations.